Literature DB >> 19901559

Context dependent neuroprotective properties of prion protein (PrP).

Andrew D Steele1, Zhipeng Zhou, Walker S Jackson, Chunni Zhu, Pavan Auluck, Michael A Moskowitz, Marie-Francoise Chesselet, Susan Lindquist.   

Abstract

Although it has been known for more than twenty years that an aberrant conformation of the prion protein (PrP) is the causative agent in prion diseases, the role of PrP in normal biology is undetermined. Numerous studies have suggested a protective function for PrP, including protection from ischemic and excitotoxic lesions and several apoptotic insults. On the other hand, many observations have suggested the contrary, linking changes in PrP localization or domain structure--independent of infectious prion conformation--to severe neuronal damage. Surprisingly, a recent report suggests that PrP is a receptor for toxic oligomeric species of a-beta, a pathogenic fragment of the amyloid precursor protein, and likely contributes to disease pathogenesis of Alzheimer disease. We sought to access the role of PrP in diverse neurological disorders. First, we confirmed that PrP confers protection against ischemic damage using an acute stroke model, a well characterized association. After ischemic insult, PrP knockouts had dramatically increased infarct volumes and decreased behavioral performance compared to controls. To examine the potential of PrP's neuroprotective or neurotoxic properties in the context of other pathologies, we deleted PrP from several transgenic models of neurodegenerative disease. Deletion of PrP did not substantially alter the disease phenotypes of mouse models of Parkinson disease or tauopathy. Deletion of PrP in one of two Huntington disease models tested, R6/2, modestly slowed motor deterioration as measured on an accelerating rotarod but otherwise did not alter other major features of the disease. Finally, transgenic overexpression of PrP did not exacerbate the Huntington motor phenotype. These results suggest that PrP has a context-dependent neuroprotective function and does not broadly contribute to the disease models tested herein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901559      PMCID: PMC2807698          DOI: 10.4161/pri.3.4.10135

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  61 in total

Review 1.  Shattuck lecture--neurodegenerative diseases and prions.

Authors:  S B Prusiner
Journal:  N Engl J Med       Date:  2001-05-17       Impact factor: 91.245

2.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

3.  Variant Gerstmann-Sträussler syndrome with the P105L prion gene mutation: an unusual case with nigral degeneration and widespread neurofibrillary tangles.

Authors:  M Yamazaki; K Oyanagi; O Mori; S Kitamura; M Ohyama; A Terashi; T Kitamoto; Y Katayama
Journal:  Acta Neuropathol       Date:  1999-11       Impact factor: 17.088

4.  Prion disease resembling frontotemporal dementia and parkinsonism linked to chromosome 17.

Authors:  R Nitrini; L S Teixeira da Silva; S Rosemberg; P Caramelli; P E Carrilho; P Iughetti; M R Passos-Bueno; M Zatz; S Albrecht; A LeBlanc
Journal:  Arq Neuropsiquiatr       Date:  2001-06       Impact factor: 1.420

5.  Huntington disease phenocopy is a familial prion disease.

Authors:  R C Moore; F Xiang; J Monaghan; D Han; Z Zhang; L Edström; M Anvret; S B Prusiner
Journal:  Am J Hum Genet       Date:  2001-10-09       Impact factor: 11.025

6.  Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol.

Authors:  Jiyan Ma; Robert Wollmann; Susan Lindquist
Journal:  Science       Date:  2002-10-17       Impact factor: 47.728

Review 7.  Neurodegenerative disorders of protein aggregation.

Authors:  Barkur S Shastry
Journal:  Neurochem Int       Date:  2003-07       Impact factor: 3.921

8.  Hyperphosphorylated tau deposition parallels prion protein burden in a case of Gerstmann-Sträussler-Scheinker syndrome P102L mutation complicated with dementia.

Authors:  Keisuke Ishizawa; Takashi Komori; Tomokazu Shimazu; Toshimasa Yamamoto; Tetsuyuki Kitamoto; Kunio Shimazu; Takanori Hirose
Journal:  Acta Neuropathol       Date:  2002-05-14       Impact factor: 17.088

9.  Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.

Authors:  Michael K Lee; Wanda Stirling; Yanqun Xu; Xueying Xu; Dike Qui; Allen S Mandir; Ted M Dawson; Neal G Copeland; Nancy A Jenkins; Don L Price
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

10.  The prion protein knockout mouse: a phenotype under challenge.

Authors:  Andrew D Steele; Susan Lindquist; Adriano Aguzzi
Journal:  Prion       Date:  2007-04-25       Impact factor: 3.931

View more
  23 in total

1.  Memory impairment in transgenic Alzheimer mice requires cellular prion protein.

Authors:  David A Gimbel; Haakon B Nygaard; Erin E Coffey; Erik C Gunther; Juha Laurén; Zachary A Gimbel; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

2.  Cellular prion protein (PrP(C)) and its role in stress responses.

Authors:  Liang Zeng; Wenquan Zou; Gongxian Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

3.  Prion-like disorders: blurring the divide between transmissibility and infectivity.

Authors:  Mimi Cushman; Brian S Johnson; Oliver D King; Aaron D Gitler; James Shorter
Journal:  J Cell Sci       Date:  2010-04-15       Impact factor: 5.285

Review 4.  Is PrP the road to ruin?

Authors:  Kelly A Barton; Byron Caughey
Journal:  EMBO J       Date:  2011-05-18       Impact factor: 11.598

5.  Neuroimmunoendocrine regulation of the prion protein in neutrophils.

Authors:  Rafael M Mariante; Alberto Nóbrega; Rodrigo A P Martins; Rômulo B Areal; Maria Bellio; Rafael Linden
Journal:  J Biol Chem       Date:  2012-08-21       Impact factor: 5.157

6.  Unraveling the neuroprotective mechanisms of PrP (C) in excitotoxicity.

Authors:  Franc Llorens; José Antonio Del Río
Journal:  Prion       Date:  2012-07-01       Impact factor: 3.931

7.  Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis.

Authors:  Cheng Zhu; Matthew V Beck; Jack D Griffith; Mohanish Deshmukh; Nikolay V Dokholyan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-16       Impact factor: 11.205

8.  The fatal attraction between pro-prion and filamin A: prion as a marker in human cancers.

Authors:  Man-Sun Sy; Chaoyang Li; Shuiliang Yu; Wei Xin
Journal:  Biomark Med       Date:  2010-06       Impact factor: 2.851

9.  Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.

Authors:  C Vergara; L Ordóñez-Gutiérrez; F Wandosell; I Ferrer; J A del Río; R Gavín
Journal:  Mol Neurobiol       Date:  2014-06-26       Impact factor: 5.590

10.  Prion Protein-Hemin Interaction Upregulates Hemoglobin Synthesis: Implications for Cerebral Hemorrhage and Sporadic Creutzfeldt-Jakob Disease.

Authors:  Ajai K Tripathi; Neena Singh
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.